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ABSTRACT 
Pegfilgrastim is used to treat patients who are undergoing 
chemotherapy, in the case of neuropenia can reduce the incidence of 
infection. Pegfilgrastim is a longer acting form of filgrastim and the 
manufacturer recommends that it should not be administered within 14 
days before chemotherapy. This review article focuses on drug 
delivery technology of Pegfilgrastim (production and formulation). 
Filgrastim in combination with PEG formula Filgrastim (being 
Pegfilgrastim) will further improve the stimulator of GCF. 
 




Pegfilgrastim is used to treat patients who are undergoing chemotherapy, in the case of 
neuropenia can reduce the incidence of infection.
[1]
 Neutropenia is a serious complication that 
often occurs in chemotherapy, especially in the elderly.
[1]
 In addition to killing cancer cells, 
chemotherapy destroys normal cells.
[2]
 A substantial decrease of neutrophils, a type of white 




These drugs are used to stimulate the growth of white blood cells "healthy" in the bone 
marrow after chemotherapy is given.
[1]
 White blood cells help the body to fight infection. 




These drugs are usually given at least 24 hours after chemotherapy to stimulate the growth of 




World Journal of Pharmaceutical Research 
   SJIF Impact Factor 8.084 
Volume 9, Issue 15, 1218-1228.              Review Article           ISSN 2277– 7105 
*Corresponding Author 
Siti Malahayati 
Department of Pharmacy, 







































Article Received on  
19 October 2020, 
 
Revised on 09 Nov. 2020, 
Accepted on 29 Nov. 2020 
 
DOI: 10.20959/wjpr202015-19272 
www.wjpr.net      │      Vol 9, Issue 15, 2020.     │      ISO 9001:2015 Certified Journal │ 
Siti et al.                                                                              World Journal of Pharmaceutical Research 
 
1219 
Pegfilgrastim is a longer acting form of filgrastim and the manufacturer recommends that it 
should not be administered within 14 days before chemotherapy.
[2]
 Pegfilgrastim 
administered as a single injection.
[2]
 Pefilgastrim more profitable than the white blood cell 
stimulation products.
[2]
 Approximately 1.4 million cancer patients in the United States in 
2001, neutropenic infection protection is very important for parents, which in the next 20 





These drugs can be given as an injection under the skin (subcutaneously), the syringes 









PEGylation early studies established PEG as a ‘stealth’ polymer, as defined by its ability to 
effectively prolong the in vivo circulation half-life and mask the immunogenicity of 
biomolecules.
[4]
 In applications where the molecular weight (MW) of the conjugated PEG is 
chosen to be greater than renal clearance so as to confer a long circulation half-life of the 
drug.
[4]
 Richter and Akerblom reported in 1983 that antibodies to PEG and ovalbumin were 
raised in rabbits immunized with PEGylated ovalbumin, though PEG alone of several 
different molecular weights (MWs) showed no or poor immunogenicity in rabbits and mice 
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Figure 2: Hydrogels formed by tethering drugs to and cross-linking multi-arms of PEG 
macromonomers with cleavable b-eliminative linkers. Varying chemistry of the linker 




Polycarbonates have recently gained much interest for protein/peptide conjugation because of 
their biodegradability and synthetic ease
[4]
 Side-chain functionalization can be done either 
pre-polymerization or post-polymerization, with the latter option offering more tolerance to 
different substituents.
[4]
 The versatility of this highly modular approach was demonstrated by 
synthesis of a range of functional polycarbonates, which are of particular relevance to 
peptide/ protein–polymer conjugates, such as polycarbonates with PEG, hydroxyl-containing 





Covalent bonding of proteins with poliethylene glycol (PEG) has been the strategy of drug 
that is widely used, with the hope of improving the pharmacological characteristics of the 
therapy.
[5]
 Some of the drugs approved for clinical use PEGasparaginaseeg, PEG interfero. 
The beneficial effect of PEG-conjugated PEG is given by the unique nature itself. PEG-
conjugated polymers tend comprehensive as chain flexibility and hydration.
[2]
 PEG is 
considered suitable for derivitisasifilgrastim. The goal is to control the elimination through 





Recombinant protein technology to connect between pharmacokinetics and 
pharmacodynamics properties of molecules. Interest engineering proteins which have 
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improved therapeutic characteristics different from a simple used as a substitute for natural 
equivalent.
[5]
 The addition of polyethylene glycol (PEG) to filgrastim (G-CSF rmetHu) 
produces pegfilgrastim development. Pegfilgrastim is a long-acting form of filgrastim.
[2] 
PEG 
covalent bonding to the Nterminal amine groups of molecules used to be in the reduction 








Look at pictures 3. Volume disproportionately occupied by PEG though serupamassa 






Each syringe contains 6 mg pegfilgrastim (Produced in Escherichia coli cells by recombinant 
DNA technology followed by conjugation with PEG) in 0.6 mL solution for injection. The 
concentration of pegfilgrastim is 10 mg / mL based on protein alone. The PEG concentration 





 Acetic acid pH 4.  
 Sorbitol (E420) 
 Polysorbat 20 
 Aqua for injecton[3] 
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Cancer patients found results that were not linear in the increase and decrease in dosage.
[6]
 
The concentration of pegfilgrastim decreased rapidly at the beginning of neutrophil recovery 
followed by myelosuppressive chemotherapy, besides that body weight was also a factor. 
Patients with high body weight will increase systemic levels higher than pegfilgrastim after 
the normal dose is given.
[6]
 Pharmacokinetic parameters of filgrastim in cancer patients after 
administration subcutaneously is Cmax:: 78.3-175ng / mL, T1/2: 25-49 hr AUC0-x : 5640-15-





Faramakokinetik of filgrastim has been studied in healthy volunteers after single intravenous 
and subcutaneous dose and multiple dose subcutaneous.
[1]
 The first kinetic elimination t1 / 22.7 
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To reduce the incidence of infection, as manifested by febrile neutropenia, in patients with 
non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs. Dose is given 6 
mg, for children or adults with small stature (weighing less than 45 kg).
[6]
 Use should be no 
more than 14 days.
[6] 
 
a. Place in pharmacotherapy 
Hematopoietic colony-stimulating factors (CSFs) such as granulocyte CSF (G-CSF; fi 
lgrastim), pegylatedG-CSF (peg fi lgrastim), or granulocyte-macrophage CSF (GM-CSF; 
sargramostim) are important adjuncts in Cancer Patients.
[8]
 Studies in Cancer Patients 
receiving myelosuppressive or myeloablative chemotherapy have demonstrated that 
concurrent use of the CSFs can reduce the duration of neutropenia.
[8]
 Hematopoietic growth 
factors (more speci fi cally G-CSF [filgrastim] or pegylated G-CSF [peg fi lgrastim]) reduce 
the risk of chemotherapy-induced febrile neutropenia.
[8]
 Granulocyte-colony stimulating 
factors (G-CSFs), such as filgrastim and pegfilgrastim, may be used as primary or secondary 




Prophylactic administration of CSFs can be used to reduce the myelosuppressive effects of 
cytotoxic chemotherapy.
[8]
 Three CSFs-granulocyte colony-stimulating factor (G-CSF 
[filgrastim]), granulocyte-macrophagecolony-stimulating factor (GM-CSF [sargramostim]), 
and a pegylated long-acting form of filgrastim, pegfilgrastim-are available in the United 
States.
[8]
 Reviews These products were approved by the US Food and Drug Administration 
(FDA) to Enhance neutrophil recovery after chemotherapy.
[8]
 Pegfilgrastim was developed 
with the aim of providing the same pharmacologic bene fi t as fi lgrastim while offering the 




Pegfilgrastim is a pegylated derivative of filgrastim, leading to a slower release and sustained 
elevation of neutrophils for up to 14 days.
[9]
 In solid tumors or malignant lymphomas, Several 
meta-analyzes revealed that prophylactic administration of G-CSFs (filgrastim or 
lenograstim) after chemotherapy Effectively reduced the frequency of febrile neutropenia and 
documented infections.
[9]
 However, it is unclear whether pegfilgrastim reduces the 
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b. Adverse effect 
 
Table 1: Most frequently* reported adverse effect reactions in randomized clinical trials 
with filgastim as comparator.
[10]
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Table 2: Most frequently* reported adverse effect reactions in randomized clinical trials 





Biosimilar according to the World Health Organization (WHO) is a term used for biological 
drugs that have characteristics similar to approved biological drugs (originators) or can be 
made when the originator's drug patent period is up, but not identical. These similarities 
include regulation, production processes, quality, safety, purity and potential or efficacy.
[11]
 
Biosimilar can be recombinant therapeutic proteins, hormones and antibodies.
[11]
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Use in indonesia 
Name : Neulastim Syringe
[13]
  
Contents : Pegfilgrastim 6 mg 0.6 mL (10 mg / mL) solution for injection
[13]
 
Dosage forms : Injection
[13]
 
Indication : Reducing the duration of neutropenia (decrease in white blood cell count of 
neutrophils in the blood) and the incidence of febrile neutropenia in patients treated with 
cytotoxic chemotherapy for non-myeloid malignancies.
[13]
 
Packaging : Prefilled syringe 6 mg / 0.6ml x 1 seed
13
 
Dose : 0.5 MU / kg body weight / day.
[13]
 
1 vial 30 MU / ml can be given to patients with a body weight of 60 kg / day.
[13]
 




Giving old : Given for 2 weeks.
[13]
 
Sign in Insurance : Not included in the insurance BPJS.
[13]
 
Drug stability  : Stable kept for 24 Months
[13]
 
Storage : At 2-8 Temperature ⁰C[13] 
 




In the normal individual G-CSF (granulosa Colony Stimulating Factor) will be stimulated 
normally. While in cancer patients, cancer drugs can reduce the consumption of G-CSF. 
While filgrastim can serve to help improve G-CSF. In combination with PEG formula 
Filgrastim (being Pegfilgrastim) will further improve the stimulator of GCF. 
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